Olysio’s Stronger-Than-Expected Sales Drive Strong Quarter For J&J
This article was originally published in The Pink Sheet Daily
Executive Summary
Products launched since 2009 have yielded the highest pharmaceutical sales growth among the 10 biggest biopharma companies, more than offsetting a substantial patent cliff. Zytiga and Olysio already have passed the $1 billion sales threshold this year, with Xarelto on pace to do so.